Agilent Technologies Declares Quarterly Dividend of $0.255
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of $0.255 per share, consistent with previous announcements, reflecting the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of this dividend stands at 0.9%, which, while relatively low, still offers a return in the current market environment, potentially increasing investor interest in the company's stock.
- Consistent Dividend Payments: Agilent has now announced a dividend of $0.255 for three consecutive quarters, indicating confidence in future cash flows and potentially enhancing market perceptions of its financial health.
- Shareholder Record Date: The dividend will be payable on July 22 for shareholders of record on June 30, with the ex-dividend date also set for June 30, ensuring timely returns for shareholders and further solidifying trust between the company and its investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.790
Low
160.00
Averages
171.67
High
180.00
Current: 114.790
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilent Technologies Declares Quarterly Dividend of $0.255
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of $0.255 per share, consistent with previous announcements, reflecting the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of this dividend stands at 0.9%, which, while relatively low, still offers a return in the current market environment, potentially increasing investor interest in the company's stock.
- Consistent Dividend Payments: Agilent has now announced a dividend of $0.255 for three consecutive quarters, indicating confidence in future cash flows and potentially enhancing market perceptions of its financial health.
- Shareholder Record Date: The dividend will be payable on July 22 for shareholders of record on June 30, with the ex-dividend date also set for June 30, ensuring timely returns for shareholders and further solidifying trust between the company and its investors.
See More
Agilent Technologies Announces Quarterly Dividend
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of 25.5 cents per share, to be paid on July 22, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Shareholder Record Date: The dividend will be distributed to all shareholders of record as of the close of business on June 30, 2026, ensuring timely benefits for investors.
- Future Dividend Uncertainty: The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors, reflecting a cautious approach to financial management.
- Company Financial Overview: Agilent generated $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people globally, showcasing its leadership in analytical and clinical laboratory technologies.
See More
Agilent Launches New Technology to Enhance Airport Security Efficiency
- Technology Deployment: Agilent will roll out its Bulk Alarm Resolution Technology (BRT) at airport security checkpoints in FIFA World Cup host cities across the U.S., aimed at improving screening efficiency for liquids, powders, and solids, thereby easing congestion during peak travel demand.
- Contract Approval: The deployment of this technology is part of a contract awarded to Agilent by the Transportation Security Administration (TSA), marking a significant milestone in the modernization of aviation security infrastructure and expected to enhance passenger and security operations efficiency.
- Rapid Detection Capability: The BRT utilizes Surface Offset Raman Spectroscopy (SORS) and advanced software to resolve alarms involving liquids, gels, solids, and powders more quickly and accurately, thereby improving the accuracy and efficiency of security screenings.
- World Cup Impact: The 2026 FIFA World Cup will be the largest tournament to date, expected to attract a massive influx of passengers, and Agilent's new technology will provide essential support to manage this surge, enhancing its competitive position in the market.
See More
Virtus and Lloyds Plan to Restart Chemaf Production
- Production Restart Plan: Virtus Minerals and Lloyds Metals & Energy plan to restart full production at Chemaf in the Democratic Republic of Congo in January 2027, marking the first comprehensive production under a U.S.-backed acquisition, which is expected to significantly enhance copper and cobalt supply capabilities in the region.
- Acquisition Details: Virtus acquired Chemaf's mines for $30 million in March and agreed to assume about $900 million in debt, a transaction that not only strengthens its position in the critical minerals sector but also provides U.S. markets with mineral resources redirected from China.
- Production Suspension for Maintenance: The new management has decided to temporarily suspend production at the Lubumbashi site for up to two months for maintenance while accelerating preparations for production at both Kolwezi and Lubumbashi to ensure full production by January 2027.
- Leadership Changes: The new CEO of Chemaf is A.N. Subramaniyam from India, with specialists from Lloyds Metals working alongside Chemaf teams to ensure operational continuity and the smooth advancement of the Mutoshi copper and cobalt project, which has been stalled since 2019 due to financial and operational challenges.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Synthego Welcomes Supreme Court Ruling Finalizing Invalidation of Agilent CRISPR Patents
- Legal Challenge Concluded: The U.S. Supreme Court denied Agilent Technologies' petition, effectively concluding a multi-year legal battle and solidifying the invalidation of two CRISPR-related patents, thereby removing significant legal barriers to gene editing technologies.
- Patent Invalidation Affirmed: The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals, confirming that Agilent's patents (Nos. 10,337,001 and 10,900,034) are unpatentable, fostering a more open environment for scientific innovation.
- Innovation Promotion: Synthego's CEO Craig Christianson emphasized that this ruling is not just about resolving a single dispute but reflects a commitment to the scientific community, aiming to clear patent obstacles in gene editing to enhance innovation for researchers and therapeutic developers.
- New Product Development: With the patents invalidated, Synthego plans to introduce novel nucleases and CRISPR technologies, further solidifying its leadership in the cell and gene therapy space and accelerating scientific discovery.
See More
Agilent Technologies Declares Quarterly Dividend of $0.255
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of $0.255 per share, consistent with previous announcements, reflecting the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of this dividend stands at 0.9%, which, while relatively low, still offers a return in the current market environment, potentially increasing investor interest in the company's stock.
- Consistent Dividend Payments: Agilent has now announced a dividend of $0.255 for three consecutive quarters, indicating confidence in future cash flows and potentially enhancing market perceptions of its financial health.
- Shareholder Record Date: The dividend will be payable on July 22 for shareholders of record on June 30, with the ex-dividend date also set for June 30, ensuring timely returns for shareholders and further solidifying trust between the company and its investors.
See More
Agilent Technologies Announces Quarterly Dividend
- Quarterly Dividend Announcement: Agilent Technologies has declared a quarterly dividend of 25.5 cents per share, to be paid on July 22, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Shareholder Record Date: The dividend will be distributed to all shareholders of record as of the close of business on June 30, 2026, ensuring timely benefits for investors.
- Future Dividend Uncertainty: The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors, reflecting a cautious approach to financial management.
- Company Financial Overview: Agilent generated $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people globally, showcasing its leadership in analytical and clinical laboratory technologies.
See More
Agilent Launches New Technology to Enhance Airport Security Efficiency
- Technology Deployment: Agilent will roll out its Bulk Alarm Resolution Technology (BRT) at airport security checkpoints in FIFA World Cup host cities across the U.S., aimed at improving screening efficiency for liquids, powders, and solids, thereby easing congestion during peak travel demand.
- Contract Approval: The deployment of this technology is part of a contract awarded to Agilent by the Transportation Security Administration (TSA), marking a significant milestone in the modernization of aviation security infrastructure and expected to enhance passenger and security operations efficiency.
- Rapid Detection Capability: The BRT utilizes Surface Offset Raman Spectroscopy (SORS) and advanced software to resolve alarms involving liquids, gels, solids, and powders more quickly and accurately, thereby improving the accuracy and efficiency of security screenings.
- World Cup Impact: The 2026 FIFA World Cup will be the largest tournament to date, expected to attract a massive influx of passengers, and Agilent's new technology will provide essential support to manage this surge, enhancing its competitive position in the market.
See More
Virtus and Lloyds Plan to Restart Chemaf Production
- Production Restart Plan: Virtus Minerals and Lloyds Metals & Energy plan to restart full production at Chemaf in the Democratic Republic of Congo in January 2027, marking the first comprehensive production under a U.S.-backed acquisition, which is expected to significantly enhance copper and cobalt supply capabilities in the region.
- Acquisition Details: Virtus acquired Chemaf's mines for $30 million in March and agreed to assume about $900 million in debt, a transaction that not only strengthens its position in the critical minerals sector but also provides U.S. markets with mineral resources redirected from China.
- Production Suspension for Maintenance: The new management has decided to temporarily suspend production at the Lubumbashi site for up to two months for maintenance while accelerating preparations for production at both Kolwezi and Lubumbashi to ensure full production by January 2027.
- Leadership Changes: The new CEO of Chemaf is A.N. Subramaniyam from India, with specialists from Lloyds Metals working alongside Chemaf teams to ensure operational continuity and the smooth advancement of the Mutoshi copper and cobalt project, which has been stalled since 2019 due to financial and operational challenges.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Synthego Welcomes Supreme Court Ruling Finalizing Invalidation of Agilent CRISPR Patents
- Legal Challenge Concluded: The U.S. Supreme Court denied Agilent Technologies' petition, effectively concluding a multi-year legal battle and solidifying the invalidation of two CRISPR-related patents, thereby removing significant legal barriers to gene editing technologies.
- Patent Invalidation Affirmed: The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals, confirming that Agilent's patents (Nos. 10,337,001 and 10,900,034) are unpatentable, fostering a more open environment for scientific innovation.
- Innovation Promotion: Synthego's CEO Craig Christianson emphasized that this ruling is not just about resolving a single dispute but reflects a commitment to the scientific community, aiming to clear patent obstacles in gene editing to enhance innovation for researchers and therapeutic developers.
- New Product Development: With the patents invalidated, Synthego plans to introduce novel nucleases and CRISPR technologies, further solidifying its leadership in the cell and gene therapy space and accelerating scientific discovery.
See More
